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The influence of HIV Env glycosylation on the conformation of the third variable domain (V3) of Env was studied by both
deglycosylation of mature Env and the use of Env produced by recombinant systems in which a-glucosidase activity was
inhibited by either deoxynojirimycin (DNM) or mutation. Selective deglycosylation affected anti-V3 antibody binding. The
immunoreactivity and sensitivity to thrombin cleavage of V3 presented on Env produced in baby hamster kidney cells were
changed by DNM treatment. In contrast, Env expressed in a-glucosidase I-deficient Chinese hamster ovary cells or in their
parental cells treated by DNM fully retained these V3 properties. These results are discussed in relation to the inconsistent
data obtained on V3 property changes resulting from Env glycosylation changes. © 1998 Academic Press
The mature human immunodeficiency virus (HIV) type
I envelope (Env) contains gp120 and gp41, the cleavage
products of the gp160 precursor: gp120 mediates HIV-
binding to CD41 cells (1) and interacts with chemokine
receptors (2) as part of post CD4-binding events leading
to gp41-mediated fusion between the virus and the host
cell membrane which is followed by virus entry (1).
The third variable domain of gp120 (V3) is the principal
neutralizing determinant (3). V3 is also largely responsi-
ble for HIV tropism to either macrophages or T-cell lines,
partially through its selective interaction with chemokine
receptors (2, 4, 5). It is a 35-amino-acid (aa) disulfide-
bonded loop which usually has one glycosylation site at
its N-terminus and a conserved motif at its crown (3).
Cleavage within this motif (GPGR1AFVT) by thrombin-
like proteases may be involved in the Env conformation
changes required for gp41 to induce membrane fusion
(6). There are many lines of evidence that V3 sensitivity to
thrombin cleavage, post-CD4-binding events and HIV
infectivity are connected: (i) V3 susceptibility to thrombin
cleavage is correlated with tropism to T-cell lines or
macrophages (7, 8), (ii) antibodies preventing V3 cleav-
age by thrombin also inhibit membrane fusion (9), (iii)
synthetic humate analogs derived from hydroquinone
inhibit HIV infectivity by interference with the CD4-in-
duced proteolytic cleavage of V3 (10), (iv) ‘‘thrombin is
less active with primary gp120 proteins compared to the
laboratory adapted MN strain’’ (11), (v) CD4 binding may
induce and stabilize a trans to cis isomerization of the
highly conserved Pro313, which would be essential for
thrombin cleavage and subsequent infection (12).
Env is heavily glycosylated. In BHK-21 cells and in
CHO cells, about 10 high mannose and hybrid structures
and 15 complex glycans make up 50% of its molecular
mass (13, 14). They are involved in Env folding (13–15)
during biosynthesis as inhibitors of a-glucosidases—
such as deoxynojirimicin (DNM) which leads to the pro-
duction of glycoproteins carrying predominantly neutral
glucosylated high mannose type glycans (16)—impair
HIV infectivity in lymphocyte cultures (17–24). DNM may
act partially by changing Env conformation (25–27). After
biosynthesis, glycans are involved in Env resistance to
various proteases (28), including thrombin (29).
The effects of changes in Env glycosylation on the
conformation characteristics of its V3 loop are not clear
(13–15). For example, in some studies, the binding of
anti-V3 antibodies is affected by DNM (25, 27), whereas,
in other studies, apparently discrepant results were ob-
tained (26, 30, 31). The lack of agreement in the pub-
lished results has been attributed to differences in the
assays used or to the glycosylation patterns of Env from
various cell origins (discussed in 13–15). Because recent
studies suggest that V3 is very important in the post-
CD4-binding events (summarized in 32), we felt that it
was necessary to investigate the effect of Env glycosy-
lation on the conformation of V3 to clarify this issue. We
studied the effect on V3 properties of abnormal EnvLai
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glycosylation resulting from specific deglycosylation or
from Env expression in cell systems where glucosidase
activity was inhibited either by DNM or by mutation. We
used both anti-V3 antibody binding and V3 susceptibility
to thrombin to assess V3 conformation, as previously
described (6–9, 25–27, 29, 31, 33–36).
The effect of glycosidase treatment of mature Env on
V3 conformation was studied. Purified soluble gp160
produced in baby hamster kidney (BHK-21) cells via a
recombinant Env expressing vaccinia virus vector
(VV1163; Transge`ne S. A., Strasbourg, France; on the
authentic HIV-1Lai env gene, the sequence correspond-
ing to cleavage sites has been altered and the trans-
membrane domain has been removed, as described in
(37)) was radiolabeled (25 mCi/mg; 28). We used an assay
which detects changes in V3 reactivity in relation to
changes in Env glycosylation (25, 27). Native Env and Env
treated by endoglycosidase H (Boehringer Mannheim,
Germany; in Ref. 29, the extent to which specific glyco-
sidase treatments affect Env glycosylation is character-
ized), which cleaves high mannose structures, reacted
similarly with 110-A (purchased from Institut Pasteur,
Paris, France, 0 to 2 mg/well; epitope: IQRGP N-terminal
to the thrombin cleavage site) and 110-H (Institut Pasteur;
0 to 2 mg/well; epitope: GPGRAFVTI at the crown of the
loop) monoclonal antibodies (mAb) adsorbed onto micro-
titer wells (Nunc, Roskild, Denmark) (Figs. 1A and 1B).
Treatment of Env with neuraminidase (type X; Sigma, St.
Louis, MO; 29) to cleave sialic acid residues or with
N-glycanase (Boehringer; 29) to fully deglycosylate Env
resulted in changes in V3 immunoreactivity. V3 accessi-
bility was also tested by susceptibility to thrombin cleav-
age: the various Env species were incubated overnight at
37°C with thrombin (0 to 150 mU/100 ml). They were then
incubated in anti-V3 mAb coated wells (1 mg/well). As
previously reported (6), mAbs directed against the crown
of V3 (110-H and 9305 (DuPont de Nemours, Dreieich,
Germany; IQRGPGRAFVTIGR) encompassing the throm-
bin cleavage site did not recognize Env once it was
cleaved by thrombin within V3, whereas the binding of
thrombin-treated Env to 110-A or 41a9 (Institut Pasteur;
directed against gp41 aa 605–609) mAbs was un-
changed (Fig. 2A). Treatment by 30 mU of thrombin re-
sulted in a 50% loss of Env binding to mAb 110-H regard-
less of glycosylation state. Binding to 110-A mAb was
assessed to evaluate the potential reactivity of the vari-
ous Env samples after treatment with the maximal dose
of thrombin and it was unaffected (Fig. 2B). Thus, degly-
cosylation of Env, after biosynthesis, slightly affected V3
immunoreactivity but did not affect V3 susceptibility to
thrombin.
DNM (4 mM) exerts a major effect on the glycosylation
pattern of glycoproteins produced by various mammalian
cell lines (16), including Env expressed in BHK-21 cells
and in CHO cells (25, 31). BHK-21 cells were treated for
2 weeks (25) by DNM and then infected with VV1163. The
effects of the abnormal glycosylation of Env induced by
DNM during biosynthesis on the characteristics of V3
was studied. Equivalent amounts of Env (0 to 100 ng/well
assessed by dot-blot quantitation as in (25)) expressed in
the presence (DNM1) or absence (DNM2) of DNM were
adsorbed onto wells coated with 41a9 mAb (1 mg/well).
The binding of both species was similar (data not
shown). Env was detected by either 110-A or 110-H mAb
labeled as in Ref. 28 (30mCi/mg). The binding of both
mAbs to DNM1Env was about three times lower than
binding to DNM2Env (Figs. 1C and 1D). The susceptibil-
ity to thrombin (0 to 125 mU/100 ml) of these two prepa-
rations adsorbed onto 41a9-coated wells was also as-
sessed. Treatment of DNM2Env (50 ng/well) with about
30 mU of thrombin resulted in a 50% decrease in binding
of 110-H, which is consistent with both the data pre-
sented in Fig. 2A and the results of SDS–PAGE analysis
(29). In contrast, 3 mU of thrombin was sufficient to
achieve a similar cleavage of the V3 loop of DNM1Env
(Fig. 2C). These results suggest that there are changes in
the V3 conformation of Env produced by BHK-21 cells as
a result of DNM-induced changes in glycosylation.
These results conflict with reports of the lack of
effect of DNM on anti-V3 antibody binding to Env
expressed in Chinese hamster ovary (CHO) cells (26,
31). We thus investigated, using the assays described
above, the conformation properties of the V3 loop of
Env expressed by an original recombinant system, i.e.,
CHO cells in which a-glucosidase activity was inhib-
ited either by DNM treatment or by a-glucosidase
mutation. The recombinant vaccinia virus vector used
to express Env in CHO cells was obtained as de-
scribed in (30) by coinfection of CHO cells with VV9-1
(37; it contains the authentic HIV-1Laienv) and with
VV6-3 (30; it contains the cowpox virus CPV hr gene to
allow replication in CHO cells). gp120 encoded by env
expressed by this vector in CHO cells and gp160
produced via VV1163 in BHK-21 cells are equally ex-
pressed and follow identical glycosylation and folding
pathways (31, 38). Env was then expressed in Lec 23,
an a-glucosidase I deficient CHO cell line (39), in the
presence or absence of DNM to inhibit any residual
a-glucosidase activity or from its parental cell line in
the presence or absence of DNM as described in (25,
31). Env synthesized in the presence of DNM or in
Lec23 cells presents a glycosylation pattern consis-
tent with the presence of large glucosylated high man-
nose structures (30, 31). All Env species (0 to 100
ng/well) bound to wells coated with D7324 (Aalto,
Dublin, Eire; 200 ng/well; a polyclonal Ab against the
C-terminus of gp120 that recognizes Env irrespective
of its glycosylation state (26 and data not shown)) and
reacted similarly with 110-A or 110-H mAb (Figs. 1E
and 1F). As expected, in the absence of DNM, the
cleaved secreted form of gp120 produced in this ex-
periment and the soluble gp160 species expressed via
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VV1163 as described above reacted similarly with the
anti-V3 mAbs studied here (Fig. 1; C compared with E
and D/F). The V3 susceptibility to thrombin (0 to 125
mU/100 ml) of these preparations (50 ng/well) was also
assessed after adsorption onto D7324-coated wells
(Fig. 2D): treatment with 3 mU of thrombin resulted in
a 50% decrease in binding to 110-H, irrespective of the
cellular origin of Env. Binding to 110-A mAb was not
affected by thrombin treatment, indicating that it did
not reduce adsorption of Env to the solid phase. Thus,
the V3 conformation of Env produced by CHO cells
was not affected by a-glucosidase I deficiency or DNM
treatment.
We confirm and expand here previous reports on the
relationship between Env glycosylation and V3 confor-
mation. Our results are consistent with previous works
showing that desialylation of mature Env increases V3
immunoreactivity (26), whereas its deglycosylation re-
FIG. 1. Immunoreactivity of the V3 loop of differently glycosylated Env. Labeled Env (5 3 104 cpm) treated with various glycosidases (Sialidase
(Sial2), Endo H (HMT2), or N-glycanase (CHO2)) or mock treated (CHO1) was adsorbed onto wells coated with increasing amounts of 110-A (A)- or
110-H (B)-mAbs; bound radioactivity was counted. Env (0 to 100 ng/well) expressed in BHK-21 cells in the presence (DNM1) or absence (DNM2) of
DNM was adsorbed onto 41a9-coated wells and stained with either [125I]110-A (C) or [125I]110-H (D) mAbs (3 105 cpm). DNM1 or DNM2 Env (0 to 100
ng/well) expressed in CHO cells (1, parent cells; 3, a-glucosidase I deficient Lec23 cells) was adsorbed onto D7324-coated wells and stained with
either [125I]110-A (E) or [125I]110-H (F) mAbs. A representative experiment (n 5 3) is shown.
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duces anti-V3 antibody binding (25, 33). Changes in
Env glycosylation during biosynthesis affect the prop-
erties of V3: the abnormal glycosylation of Env result-
ing from DNM treatment of insect or mammalian cells
affects both anti-V3 antibody binding (25, 27) and sen-
sitivity to thrombin (24), as observed here for BHK-21
derived Env. Surprisingly, two independent groups ob-
served that Env expressed in CHO cells in which
a-glucosidase activity is inhibited retains its ability to
mediate membrane fusion (30, 31), its V3 immunore-
activity (26, 30, 31), and its sensitivity to thrombin (26).
These reports are consistent with our data using both
Lec23 cell line and its parental CHO cell line. Thus, it
is clear that cell origin is the main cause of the
discrepancies in the previous results discussed else-
where (13–15, 31). The influence of the cell origin on
the properties of V3 can be infered also from the
observation that 10 times more thrombin was required
to cleave BHK-21 cell-derived soluble gp160 (our data
presented here) and BHK-21 cell-associated gp120
(M.-J. Papandre´ou and E. Fenouillet, unpublished data)
than for CHO cell-derived Env (our data presented
here).
Further investigation of the impact of DNM on V3
structure should be carried out as one of the many
strategies for preventing HIV infectivity. Indeed, in light
of the recent literature, the central involvement of V3 in
the various post-CD4-binding events leading to cell
infection by HIV is clear (2) and our results suggest
that the abnormal conformation of V3 induced by DNM
treatment may be responsible for its effect on both the
ability of Env to mediate membrane fusion and HIV
infectivity (13–15).
The lack of effect of DNM in the CHO cell lines
suggests that some cell lines, e.g., Lec23 cells, can
develop alternative biosynthetic pathways (40–42) to
overcome a-glucosidase deficiency and to allow the
normal processing of Env required for correct folding.
Such alternative biosynthetic pathways might be the
emergence of an a-endomannosidase activity—which
FIG. 2. Susceptibility to thrombin of the V3 loop of differently glycosylated Env. Effect of thrombin cleavage on mAb binding to Env: [125I]gp160 was
treated by thrombin (0 to 150 mU/100ml) and then incubated in 110-H-, 110-A-, 41a9-, or 9305-coated wells; bound radioactivity was counted (A).
Labeled Env was treated with various glycosidases (Sialidase (Sial2), Endo H (HMT2), or N-glycanase (CHO2)) or mock treated (CHO1) and then
treated by thrombin (0 to 150 mU/100 ml) and further incubated in 110-H-coated wells; bound radioactivity was counted (B). Env expressed in BHK-21
cells in the presence (DNM1) or absence (DNM2) of DNM was treated by thrombin (0 to 125 mU/100 ml), adsorbed onto 41a9-coated wells and
stained with [125I]110-H (C). DNM1 or DNM2 Env expressed in CHO cells (1, parent cells; 3, a-glucosidase I deficient Lec23 cells) was treated by
thrombin (0 to 125 mU/100 ml), adsorbed onto D7324-coated wells and stained with [125I]110-H (D). (Inset) As a control, the binding to [125I]110-A of
the various Env species treated with the maximum dose of thrombin used was assessed. A representative experiment (n 5 3) is shown.
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may cleave Glc3Man9GlcNAc2 into Glc3Man and
Man8GlcNAc2 (41)—or of a partially DNM-resistant
a-glucosidase. It is also possible that the overexpres-
sion of a chaperone may overcome the effects of DNM
on folding in the endoplasmic reticulum (40). Such
pathways may also occur in vivo and may partially
explain why N-butyl DNM was not effective in anti-HIV
trials (43).
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